<DOC>
	<DOCNO>NCT01627821</DOCNO>
	<brief_summary>This investigation conduct interventional intention-to-treat clinical study population end stage heart failure patient meet specific inclusion exclusion criterion . The multi-center study prospective , dual-armed , non-blinded ( open-label ) randomize , compare treatment group receive Jarvik 2000 LVAS Post-Auricular Connector active control group treat PMA approve Thoratec HeartMateÂ® II LVAS Destination Therapy .</brief_summary>
	<brief_title>Evaluation Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector -- Destination Therapy Study</brief_title>
	<detailed_description>Study Success Primary Endpoint A establish proportion subject Treatment Group meeting Subject Success Criteria A , determine non-inferior Control Group ( two year ) accord pre-specified statistical analysis . Subject composite success require subject achieve Effectiveness Endpoint : 1 . Two year actuarial survival 2 . Freedom procedure repair , replace implanted device 3 . Freedom stroke result Modified Rankin Score &gt; 3 two-year follow-up Study Success Primary Endpoint B establish proportion subject Treatment Group meeting Subject Success Criteria B determine superior Control Group ( three year ) accord pre-specified statistical analysis . Subject composite success require subject achieve Effectiveness Endpoint : 1 . Three year survival 2 . Freedom serious adverse event drive cable pump pocket infection</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Cardiac transplantation ineligible . 2 . Late stage heart failure NYHA Class IIIb IV least 45 past 60 day . 3 . Cardiac Index &lt; 2.2 L / min / m2 4 . LVEF = 25 % less 5 . Patients Optimal Medical Management ( OMM ) define Section 9.2 OR dependent intraaortic balloon counterpulsation 7 day OR temporary ( indicated 30 day use , less ) mechanical circulatory support 7 day , OR support IV inotropes 7 day fail respond . 6 . BSA &gt; 1.2 m2 &lt; 2.5 m2 . 1 . History cardiac transplantation leave ventricular reduction procedure . 2 . Clinical condition , heart failure , could limit survival less three year . 3 . Cause heart failure due , associate , uncorrected thyroid disease , obstructive / restrictive cardiomyopathy , pericardial disease , amyloidosis , dermatomyositis , active myocarditis . 4 . Intolerance anticoagulation antiaggregation therapy require postoperative therapy . 5 . Known sensitivity product bovine origin . The Jarvik 2000 incorporate Hemashield vascular graft . Patients know sensitivity product bovine origin implant . 6 . Chronic immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>